Literature DB >> 7092953

Macromolecular interactions of [14C-ring]melphalan in blood.

A E Ahmed, T F Hsu, R A el-Azhary, H Moawad, J Costanzi.   

Abstract

The pharmacokinetics and macromolecular interactions of [14C-ring]melphalan (L-PAM) in blood were studied in rats following a single oral dose (20 mg/kg, 0.1 mCi/kg). Radioactivity levels were monitored in blood over a period of 72 hr. The highest levels of radioactivity were observed at 2 hr. The decline of radioactivity from the blood was biphasic with T1/2 alpha = 7 hr and T1/2 beta = 75 hr. The radioactive species in plasma corresponded to unchanged L-PAM and its two known hydrolytic products 4,2-hydroxyethyl 2-chloroethylamino-L-phenylalanine (L-MOH) and 4-[bis(2-hydroxyethyl)amino]-L-phenylalanine (L-DOH). In addition, four other major, previously unknown, metabolites of L-PAM were detected in plasma. At 72 hr, most of the radioactivity was bound to macromolecular components, 26% to plasma macromolecules and 62% in red blood cells. Covalent binding to blood cells was mainly to membrane proteins. Binding to hemoglobin and other soluble components of the red cells was also observed, with a 5000-fold greater affinity for membranes. These studies suggest extensive interaction of melphalan, or its metabolites, with membrane and soluble proteins of red blood cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092953     DOI: 10.1016/0006-2952(82)90389-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Authors:  Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

2.  Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Authors:  S Y Lee; R S Meehan; D C Seldin; J M Sloan; K Quillen; A Shelton; D Brauneis; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

3.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat.

Authors:  A E Ahmed; T F Hsu; R A el-Azhary; H Moawad; H H Farrish; J Costanzi
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.